Effect of topical 0.05% cyclosporine for the treatment of vernal keratoconjunctivitis

Dr. Dipali Satani, Dr. Krupali Raol, Dr. Shwetambari Singh

Abstract


BACKGROUND:

To evaluate the short-term efficacy and safety of topical 0.05% cyclosporine for patients with vernal keratoconjunctivitis.

METHODS:

Fifteen patients with severe vernal keratoconjunctivitis were included in the study. All were treated with 0.05% cyclosporine eye drops. Eyes that received cyclosporine eye drops did not receive any other eye drops except 0.5% lubricating(CMC) eye drops. Symptoms and signs were scored on the day of enrolment and at the end of days1,2, 7,14,30,60,90,120,150 and 180.

RESULTS:

At the end of 7 days, no statistically significant decrease was noted from baseline in mean scores of either signs (p = 0.18) or symptoms (p = 0.50) in the eyes that received cyclosporine. On the other hand, a statistically significant decrease was observed in both sign and symptom scores (p < 0.001, for both) of eyes that received cyclosporine at the end of 14 days. At days 30 and 90, statistically significant decrease in both sign scores and symptom scores were noted compared with baseline in the eyes that received cyclosporine eye drops(p < 0.001, for all).

INTERPRETATION:

Topical 0.05% cyclosporine is effective in alleviating signs and symptoms of patients with severe vernal keratoconjunctivitis and had no observed side effects over the course of the study.Most of the therapeutic effect was achieved after 14 days. The initial therapeutic effect was maintained during the next 180 days.


Keywords


conjunctivalhyperemia palpebral conjunctiva inflammation

Full Text:

PDF

References


Leonardi A, Motterle L, Bortolotti M (2008) Allergy and the eye. ClinExpImmunol 153: 17-21.

Sunil Kumar (2009) Vernalkeratoconjunctivitis: a major review. ActaOphthalmol 87:133-147.

Kiliç A, Gürler B (2006) Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 41: 693-698.

Zepeda-Ortega B, Rosas-vargas MA, Ito Tsuchiya FM (2007) Conjuntivitisalérgica en la infancia. RevistaAlergia México 54: 41-53.

Whitcup SM, Chan CC, Luyo DA, Bo P, Li Q (1996) Topical cyclosporine inhibits mast cell-mediate conjunctivitis. Invest Ophthalmol Vis Sci 37: 2686-2693.

Bonini S, Coassin M, Aronni S, Lambiase A (2004) Vernalkeratoconjunctivitis. Eye (Lond) 18: 345-351.

Hingorani M, Lightman S (1995) Therapeutics options in ocular allergic disease. Drugs 50: 208-211.

Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, et al. (2006) Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 17: 527-532.

BenEzra D, Matamoros N, Cohen E (1988) Treatment of severe vernal keratoconjunctivitis with Cyclosporine Aeyedrops. Transplant Proc 20: 644- 649.

Avunduk AM, Avunduk MC, Erdöl H, Kapicioglu Z, Akyol N (2001) Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis.Ophthalmologica 215: 290-293.

Leonardi A, Hall A (2010) Mechanisms of corneal allergic reaction: new options for treatment. Expert Rev Ophthalmol 5: 545-556.

Belin MW, Bouchard CS, Phillips (1990) Update on topical cyclosporine A: Background, Immunology and Pharmacology. Cornea 9: 184-195.

Ozcan AA, Ersoz TR, Dulger E (2007) Management of severe allergic conjunctivitis with topical cyclosporine a 0.05% eye drops. Cornea 26: 1035- 1038.

Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R (2003) Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J pharm Biopharm 56: 307-318.

Quintana-Hau JD, Cruz-Olmos E, López-Sánchez MI, Sánchez-Castellanos V, Baiza-Durán L, et al. (2005) Characterization of the novel ophthalmic drug carrier sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno. Drug DevInd Pharm 31: 263-269.

Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S (1998) A randomized placebo-controlled trial of topical cyclosporine A in steroidedependent atopic dependent atopic keratoconjunctivitis. Ophthalmology 105: 1715-1720.

BenEzra D, Mafrzir G (1990) Ocular penetration of cyclosporine A. The rabbit eye. InvOphthalmol Vis Sci 31: 1362-1366.

Niederkorn JY (2008) Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models. CurrOpin Allergy ClinImmunol 8: 472-476.

Akpek EK, Dart JK, Watson S, Christen W, Dursun D, et al. (2004) A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis.Ophthalmology 111: 476-482.

Quintana–Hau JD, Cruz–Olmos E, Lopez–Sanchez MI, Gonzalez JR, Baiza– Duran L, et al. (2004) In vitro study of corneal retention of Cyclosporine–A from different formulations.InvestOphthalmol Vis Sci 45: E-Abstract 67.

Bleik JH, Tabbara KF (1991) Topical cyclosporine in vernal keratoconjunctivitis.Ophthalmology 98: 1679-1684.

Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, et al. (2008) Efficacy of topical cyclosporine A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol 52: 357-362.

Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, et al. (2002) Efficacy and safety of cyclosporine eye drops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 89: 298-303.

Tesse R, Spadavecchia L, Fanelli P, Rizzo G, Procoli U, et al. (2010) Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children.Pediatr Allergy Immunol. 21: 330-335.

Mendicute J, Aranzasti C, Eder F (1997) Topical cyclosporine A 2% in the treatment of of vernal keratoconjunctivitis. Eye (Lond) 11: 75-78.

Tomida I, Schlote T, Bräuning J, Heide PE, Zierhut M (2002) Cyclosporine A 2% eye drops in therapy of atopic and vernal keratoconjunctivitis. Ophthalmologe 99: 761-776.

Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, et al. (2009) A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J OculPharmacolTher 25: 365-372.

Kosrirukvongs P, Vichyanond P, Wongsawad W (2003) Vernalkeratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol 21: 25-30.


Refbacks

  • There are currently no refbacks.